TNFRSF14 (HVEM) is a novel immune checkpoint for cancer immunotherapy in humanized mice
N. Aubert, S. Brunel, D. Olive, g. marodon
This study demonstrates that targeting HVEM with a monoclonal antibody inhibits tumor growth in humanized mice by enhancing T cell activity and reducing immunosuppressive pathways.
bioRxiv · Dec 1, 2020Immunology